Dipeptidyl Peptidase 1 (DPP1) / Cathepsin C Inhibitor Market By Molecule Type (Small-Molecule Inhibitors, Biologic Inhibitors); By Indication (Generalized Pustular Psoriasis, Non-Cystic Fibrosis Bronchiectasis, Severe Chronic Periodontitis, Other Rare Neutrophil-Mediated Disorders); By Route of Administration (Oral, Subcutaneous, Injectable); By End User (Specialty Hospitals, Dermatology & Pulmonology Clinics, Research Centers, Hospital Pharmacies); By Geography, Segment Revenue Estimation, Forecast, 2024–2030

DPP1 / Cathepsin C Inhibitors Market Advances as First Approved Therapy Reshapes Neutrophilic Bronchiectasis Care (Last Updated on: June-2026)

The Global Dipeptidyl Peptidase 1 (DPP1) / Cathepsin C Inhibitor Market will witness a robust CAGR of 10.2%, valued at USD 1.2 billion in 2024, expected to reach USD 2.1 billion by 2030.

 

The DPP1 / Cathepsin C inhibitors market has moved from a pipeline-led respiratory inflammation opportunity into an early commercial drug category after the approval of brensocatib, marketed as BRINSUPRI by Insmed. The category remains narrow, but its strategic importance is high because it introduces the first approved mechanism-based treatment pathway for non-cystic fibrosis bronchiectasis, a chronic lung disease previously managed mainly through airway clearance, antibiotics, macrolides, pulmonary rehabilitation, and exacerbation control.

 

The commercial shift is not driven by another symptomatic respiratory product. It is driven by a drug class designed to interrupt a disease-relevant inflammatory pathway. Dipeptidyl peptidase 1, also known as Cathepsin C, activates neutrophil serine proteases including neutrophil elastase, proteinase 3, and cathepsin G during neutrophil maturation. Excess activity of these proteases contributes to airway inflammation, mucus dysfunction, tissue injury, recurrent infection, and repeated pulmonary exacerbations.

 

This changes the treatment logic in bronchiectasis. Instead of managing every flare after it occurs, DPP1 inhibition creates a preventive disease-control layer for patients with recurrent exacerbations and persistent neutrophilic inflammation. The market should therefore be assessed as a first-approval category: one approved anchor product defines the benchmark, while follow-on assets must prove whether the mechanism can support a broader multi-product class.

 

Market Scope and Product Coverage

The DPP1 / Cathepsin C inhibitors market covers oral small-molecule therapies designed to inhibit Cathepsin C activity and suppress activation of neutrophil serine proteases. The current commercial focus is non-cystic fibrosis bronchiectasis in patients aged 12 years and older, particularly those with recurrent exacerbations and continued disease burden despite background care.

Future market expansion may depend on evidence in other neutrophil-driven diseases, including chronic obstructive pulmonary disease, cystic fibrosis-related bronchiectasis, bronchial asthma, chronic rhinosinusitis, hidradenitis suppurativa, and selected inflammatory conditions. These areas should be treated as pipeline expansion opportunities rather than current commercial revenue pools.

The market does not include antibiotics, inhaled anti-infectives, bronchodilators, corticosteroids, mucolytics, airway clearance devices, or supportive respiratory care products. These therapies remain part of bronchiectasis management, but they do not define the DPP1 / Cathepsin C inhibitor category.

Drug / Asset	Company	Development Status	Market Role
Brensocatib / BRINSUPRI	Insmed	Approved in the U.S., EU, and UK	First-in-class commercial benchmark
Verducatib / BI 1291583	Boehringer Ingelheim	Phase III	Most relevant direct global follow-on competitor
HSK31858	Haisco / Chiesi	Phase III in NCFB	Important China-linked and respiratory pipeline asset
MLD-151 / MDI-0151 / MOD-A	Melodia Therapeutics / Alivexis	IND-enabling / early development	Early-stage differentiated Cathepsin C inhibitor

 

Epidemiology and Patient Population Analysis

The addressable market is anchored in non-cystic fibrosis bronchiectasis rather than the broader chronic respiratory disease population. The diagnosed pool is already large enough to support a specialty-drug category, with approximately 500,000 diagnosed NCFB patients in the United States, around 600,000 in the EU5, and nearly 150,000 in Japan. This creates a visible launch population of about 1.25 million diagnosed patients across major markets before accounting for underdiagnosis and COPD-overlap misclassification.

However, diagnosed prevalence does not directly equal treatable demand. The commercial core is concentrated in patients with CT-confirmed disease, recurrent pulmonary exacerbations, chronic sputum burden, repeated antibiotic exposure, and specialist follow-up. This makes the market clinically serious but commercially selective, because payer and physician interest will be strongest where exacerbation prevention has a clear medical and economic rationale.

Age is an important market-shaping factor. Bronchiectasis prevalence rises sharply in older adults, and older patients often carry greater comorbidity, higher healthcare utilization, and higher hospitalization risk. This supports the clinical need for preventive therapy, but it also increases the importance of chronic safety, monitoring burden, and payer confidence.

The highest-value treatment segment is not every bronchiectasis patient. It is the recurrent-exacerbator population with two or more exacerbations in the prior year, prior antibiotic-treated flares, chronic infection risk, declining lung function, and persistent symptoms despite standard care. This group is most likely to justify DPP1 inhibitor therapy because fewer exacerbations can translate into lower clinical instability, reduced antibiotic cycling, and lower acute-care burden.

 

Diagnosed, Eligible and Treated Patient Dynamics

The DPP1 / Cathepsin C inhibitor patient funnel is narrow but expandable. Diagnosis depends on chest CT confirmation, while treatment eligibility depends on exacerbation history, age, prior background therapy, specialist involvement, and documentation quality. This makes the market more access-filtered than prevalence-driven.

Brensocatib’s label creates a broad treatment opening in non-cystic fibrosis bronchiectasis patients aged 12 years and older, but real-world utilization will initially be narrower. Patients with frequent exacerbations are likely to move first because this is where clinical benefit, cost-offset logic, and physician urgency are strongest.

The treated pool will expand in stages. Early adoption will come from pulmonology practices, bronchiectasis centers, and respiratory specialty clinics already managing high-burden patients. Mid-term growth will depend on improved recognition of NCFB in patients previously treated under COPD-like pathways, more consistent CT-based confirmation, and stronger documentation of exacerbation frequency in clinical records.

The key bottleneck is not the absence of patients. It is the conversion of diagnosed patients into eligible, approved, and persistent treated patients. A patient with CT-confirmed NCFB but weak exacerbation documentation may remain commercially invisible, while a frequent exacerbator with repeated antibiotic use and specialist records becomes a high-probability treatment candidate.

 

Current Treatment Landscape and Standard of Care

Before brensocatib, bronchiectasis care was largely supportive, infection-focused, and exacerbation-reactive. Standard management included airway clearance, sputum culture monitoring, vaccination, acute antibiotics, long-term macrolides for selected frequent exacerbators, inhaled antibiotics for selected chronic infection phenotypes, pulmonary rehabilitation, and management of underlying causes.

This standard of care remains important, but it does not directly block neutrophil serine protease activation. That gap created the clinical opening for DPP1 / Cathepsin C inhibitors. Brensocatib is therefore positioned as an added disease-control therapy for patients who continue to exacerbate despite optimized background management.

The most likely early treatment position is recurrent-exacerbator bronchiectasis with persistent inflammatory burden. Physicians are likely to use DPP1 inhibition alongside existing respiratory care rather than as a replacement for infection management or airway clearance.

 

Brensocatib / BRINSUPRI Product Overview

Brensocatib is an oral, once-daily, reversible and selective DPP1 inhibitor. By blocking DPP1, it prevents activation of neutrophil serine proteases during neutrophil maturation and reduces protease-driven airway inflammation.

The product established the first commercial benchmark for the DPP1 / Cathepsin C inhibitor class. In the Phase III ASPEN program, brensocatib reduced annualized pulmonary exacerbation rates versus placebo and delayed the time to first exacerbation, supporting its role as a preventive therapy for patients with recurrent disease activity.

Safety and tolerability remain important because bronchiectasis is chronic and treatment may continue long term. Dermatologic effects, oral or periodontal events, respiratory infections, headache, and hypertension are among the monitoring areas that may influence prescribing comfort, payer criteria, patient counseling, and treatment persistence.

 

Competitive Landscape and Pipeline Outlook

The direct DPP1 / Cathepsin C inhibitor pipeline remains limited, which gives brensocatib a strong first-mover advantage. However, the class is no longer a single-asset development space. Verducatib, HSK31858, and early-stage differentiated programs create a pipeline that can validate the mechanism further and introduce competitive pressure over time.

Verducatib, also known as BI 1291583, is the most important global follow-on asset. It is being evaluated in the Phase III AIRTIVITY program for bronchiectasis. Its commercial relevance will depend on whether it can show competitive exacerbation reduction, chronic safety, convenient dosing, and a differentiated profile against the brensocatib benchmark.

HSK31858 adds an important regional and pipeline freshness signal. The asset is a potent, selective, reversible DPP1 inhibitor being developed for non-cystic fibrosis bronchiectasis and other respiratory inflammatory indications. Its progress highlights growing interest in Cathepsin C inhibition beyond Western first-mover commercialization.

MLD-151 / MDI-0151 is earlier in development and should not be treated as a near-term commercial competitor. Its relevance lies in differentiated chemistry and potential use across broader neutrophil-driven inflammatory diseases. At this stage, it adds long-term platform optionality rather than immediate market pressure.

 

Comparative Clinical Benchmarking

Benchmarking in this category will center on clinically meaningful respiratory outcomes rather than biomarker activity alone. The most important measures include annualized pulmonary exacerbation rate, time to first exacerbation, proportion of patients remaining exacerbation-free, severe exacerbation reduction, lung function trajectory, quality-of-life impact, discontinuation rates, and long-term safety.

Brensocatib currently defines the benchmark because it is approved and supported by late-stage evidence. Verducatib and HSK31858 must show whether follow-on Cathepsin C inhibition can deliver comparable or superior outcomes in broad bronchiectasis populations. Early-stage assets will be judged first on target engagement, selectivity, tissue distribution, pharmacokinetics, and safety before they become commercially relevant.

 

Pricing, Reimbursement and Market Access Dynamics

DPP1 / Cathepsin C inhibitors are entering the market as premium specialty respiratory therapies rather than low-cost chronic respiratory prescriptions. Brensocatib’s U.S. annual list price of about USD 88,000 makes payer access a central market-shaping variable from launch.

Access is expected to be favorable for clearly documented high-burden patients, but not unrestricted. U.S. payers are likely to focus on CT-confirmed NCFB, recurrent exacerbation history, prior standard-of-care use, and specialist prescribing. The label may be broad, but reimbursement is likely to behave as a severity-gated pathway in early commercialization.

Europe has moved from regulatory uncertainty into reimbursement execution after EU approval. The approved European population is more clearly tied to patients aged 12 years and older with two or more exacerbations in the previous 12 months, which reinforces the market’s frequent-exacerbator focus. UK authorization adds another freshness signal, although NICE appraisal activity remains important because authorization does not automatically translate into broad reimbursed access.

 

Commercial Strategy and Market Execution

Commercial execution will depend on how effectively DPP1 inhibition is positioned as a targeted inflammation-control layer within bronchiectasis care. The strongest launch audience is pulmonologists, bronchiectasis centers, respiratory specialty clinics, and high-volume practices already managing recurrent-exacerbator patients.

Patient identification is the main execution lever. Uptake improves when practices can identify CT-confirmed NCFB patients with repeated exacerbations, high antibiotic use, chronic sputum burden, prior hospitalization, or lung function decline. Registry development, EHR-based prompts, referral education, and documentation support can therefore directly affect treated-patient conversion.

Launch success will also depend on chronic-use confidence. Because DPP1 inhibition is not a short-course rescue therapy, physicians will need practical guidance on dermatologic monitoring, oral and periodontal care, infection surveillance, and patient adherence. The class will scale fastest where physicians see fewer exacerbations without adding an excessive monitoring burden.

 

Combination Therapy and Future Market Evolution

DPP1 / Cathepsin C inhibitors are expected to become part of layered bronchiectasis care rather than replace existing therapies. Their role is likely to be strongest in patients whose disease remains unstable despite airway clearance, infection management, and other background care.

Future market evolution may become more phenotype-based. Patients with high exacerbation frequency, neutrophilic inflammation, chronic infection burden, or COPD-bronchiectasis overlap may become priority groups for deeper clinical use. If biomarkers such as neutrophil elastase activity or sputum inflammatory signatures become more widely adopted, patient selection could become more precise.

The long-term category opportunity depends on whether DPP1 inhibition remains limited to bronchiectasis or expands into adjacent neutrophil-driven inflammatory diseases. Positive data in additional respiratory or inflammatory indications would shift the market from a single-disease specialty category into a broader neutrophilic inflammation platform.

 

Strategic Revenue Expansion Opportunities

Revenue expansion will be driven by treated-patient conversion, geographic access, payer confidence, and indication expansion. The United States remains the early anchor market because of pricing flexibility and specialty-drug infrastructure, while Europe and the UK add regulated access opportunities shaped by reimbursement decisions and health-economic review.

The strongest near-term opportunity is the diagnosed recurrent-exacerbator population already visible to pulmonologists. Longer-term growth will depend on improved bronchiectasis diagnosis, clearer treatment algorithms, broader payer acceptance, and evidence showing reductions in exacerbations, antibiotic exposure, hospital burden, and disease instability.

 

Market Outlook

The DPP1 / Cathepsin C inhibitors market is entering its first commercial formation phase. Brensocatib has validated the mechanism and created the first approved treatment pathway for non-cystic fibrosis bronchiectasis, but market expansion will be shaped by diagnosis rates, exacerbation documentation, specialist uptake, payer controls, and long-term safety confidence.

The next phase of growth will depend less on label novelty and more on real-world performance. If DPP1 inhibition consistently reduces exacerbation burden and remains manageable for chronic use, it can become a core disease-control strategy for recurrent bronchiectasis patients. Follow-on assets will determine whether the class remains first-mover led or develops into a broader competitive respiratory inflammation market.

 

Dipeptidyl Peptidase 1 (DPP1) / Cathepsin C Inhibitor Market Report Coverage Table

Report Attribute	Details
Forecast Period	2024 – 2030
Market Size Value in 2024	USD 1.2 Billion
Revenue Forecast in 2030	USD 2.1 Billion
Overall Growth Rate	CAGR of 10.2% (2024 – 2030)
Base Year for Estimation	2024
Historical Data	2019 – 2023
Unit	USD Million, CAGR (2024 – 2030)
Segmentation	By Molecule Type, By Indication, By Route of Administration, By End User, By Geography
By Molecule Type	Small-Molecule Inhibitors, Biologic Inhibitors
By Indication	Generalized Pustular Psoriasis, Non-Cystic Fibrosis Bronchiectasis, Severe Chronic Periodontitis, Other Rare Neutrophil-Mediated Disorders
By Route of Administration	Oral, Subcutaneous, Injectable
By End User	Specialty Hospitals, Dermatology & Pulmonology Clinics, Research Centers, Hospital Pharmacies
By Geography	North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Country Scope	U.S., UK, Germany, China, India, Japan, Brazil, Saudi Arabia, UAE, South Africa
Market Drivers	- Rising prevalence of rare inflammatory and neutrophil-mediated disorders - Advancements in precision medicine and biomarker-based therapy selection - Growth of biologic and targeted DPP1 inhibitor pipelines
Customization Option	Available upon request